Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
Immunotherapy trials and hyperprogressive disease

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.06.18
Views: 580
Rating:

Dr Elena Garralda - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain

Dr Garralda speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about ongoing immunotherapy trials being conducted in Vall d´Hebron.

She goes on to discuss a new definition of hyperprogression , suggested to bypass the need for a CT scan before treatment.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation